Literature DB >> 22309435

One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions.

M Calderón1, V Cardona, P Demoly.   

Abstract

Allergen immunotherapy was introduced by Leonard Noon 100 years ago and is the only disease-modifying treatment for allergic individuals. Improved understanding of immunology has taught us a great deal about the underlying mechanisms involved in allergen immunotherapy; however, despite these developments, a number of important questions remain unanswered. Several of these questions relate to the practice of allergen immunotherapy in the clinic, such as: Is it possible to unify units of allergen potency? Which treatment schedules are best? Is allergen immunotherapy effective in all patient groups? Is there a dose-response relationship for efficacy and safety?, and Is there evidence for long-term effects following allergen immunotherapy? Others are related to new developments, such as new indications, or developments in the production of allergens. On the centenary of Noon's discovery, European experts in the field of immunotherapy met in Geneva under the aegis of the EAACI to discuss these controversial issues. This study presents outcomes and conclusions from these discussions.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22309435     DOI: 10.1111/j.1398-9995.2012.02785.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  16 in total

Review 1.  Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.

Authors:  R Valenta; R Campana; K Marth; M van Hage
Journal:  J Intern Med       Date:  2012-08       Impact factor: 8.989

Review 2.  Comparative analysis of allergic rhinitis in children and adults.

Authors:  Adriana Izquierdo-Domínguez; Antonio L Valero; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

3.  A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.

Authors:  Katharina Marth; Isabella Breyer; Margarete Focke-Tejkl; Katharina Blatt; Mohamed H Shamji; Janice Layhadi; Anna Gieras; Ines Swoboda; Domen Zafred; Walter Keller; Peter Valent; Stephen R Durham; Rudolf Valenta
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

4.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Authors:  Giorgio Walter Canonica; Linda Cox; Ruby Pawankar; Carlos E Baena-Cagnani; Michael Blaiss; Sergio Bonini; Jean Bousquet; Moises Calderón; Enrico Compalati; Stephen R Durham; Roy Gerth van Wijk; Désirée Larenas-Linnemann; Harold Nelson; Giovanni Passalacqua; Oliver Pfaar; Nelson Rosário; Dermot Ryan; Lanny Rosenwasser; Peter Schmid-Grendelmeier; Gianenrico Senna; Erkka Valovirta; Hugo Van Bever; Pakit Vichyanond; Ulrich Wahn; Osman Yusuf
Journal:  World Allergy Organ J       Date:  2014-03-28       Impact factor: 4.084

5.  Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5.

Authors:  Margarete Focke-Tejkl; Raffaela Campana; Renate Reininger; Christian Lupinek; Katharina Blatt; Peter Valent; Tea Pavkov-Keller; Walter Keller; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2013-10-31       Impact factor: 10.793

Review 6.  Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis.

Authors:  K Gangl; V Niederberger; R Valenta
Journal:  Clin Exp Allergy       Date:  2013-11       Impact factor: 5.018

7.  EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.

Authors:  Moises A Calderon; Pascal Demoly; Roy Gerth van Wijk; Jean Bousquet; Aziz Sheikh; Anthony Frew; Glenis Scadding; Claus Bachert; Hans J Malling; Rudolph Valenta; Beatrice Bilo; Antonio Nieto; Cezmi Akdis; Jocelyne Just; Carmen Vidal; Eva M Varga; Emilio Alvarez-Cuesta; Barbara Bohle; Albrecht Bufe; Walter G Canonica; Victoria Cardona; Ronald Dahl; Alain Didier; Stephen R Durham; Peter Eng; Montserrat Fernandez-Rivas; Lars Jacobsen; Marek Jutel; Jörg Kleine-Tebbe; Ludger Klimek; Jan Lötvall; Carmen Moreno; Ralph Mosges; Antonella Muraro; Bodo Niggemann; Giovanni Pajno; Giovanni Passalacqua; Oliver Pfaar; Sabina Rak; Gianenrico Senna; Gabriela Senti; Erkka Valovirta; Marianne van Hage; Johannes C Virchow; Ulrich Wahn; Nikolaos Papadopoulos
Journal:  Clin Transl Allergy       Date:  2012-10-30       Impact factor: 5.871

8.  Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice.

Authors:  D Bach; R Weiss; M Hessenberger; S Kitzmueller; E E Weinberger; W D Krautgartner; C Hauser-Kronberger; C Boehler; J Thalhamer; S Scheiblhofer
Journal:  Allergy       Date:  2012-09-05       Impact factor: 13.146

9.  Murine subcutaneous immunotherapy models with beneficial immunological and physiological effects.

Authors:  Yoon-Seok Chang; Yoon-Keun Kim; Sae-Hoon Kim; Heung-Woo Park; Kyung-Up Min; You-Young Kim; Sang-Heon Cho
Journal:  Asia Pac Allergy       Date:  2013-01-30

10.  Research needs in allergy: an EAACI position paper, in collaboration with EFA.

Authors:  Nikolaos G Papadopoulos; Ioana Agache; Sevim Bavbek; Beatrice M Bilo; Fulvio Braido; Victoria Cardona; Adnan Custovic; Jan Demonchy; Pascal Demoly; Philippe Eigenmann; Jacques Gayraud; Clive Grattan; Enrico Heffler; Peter W Hellings; Marek Jutel; Edward Knol; Jan Lötvall; Antonella Muraro; Lars K Poulsen; Graham Roberts; Peter Schmid-Grendelmeier; Chrysanthi Skevaki; Massimo Triggiani; Ronald Vanree; Thomas Werfel; Breda Flood; Susanna Palkonen; Roberta Savli; Pia Allegri; Isabella Annesi-Maesano; Francesco Annunziato; Dario Antolin-Amerigo; Christian Apfelbacher; Miguel Blanca; Ewa Bogacka; Patrizia Bonadonna; Matteo Bonini; Onur Boyman; Knut Brockow; Peter Burney; Jeroen Buters; Indre Butiene; Moises Calderon; Lars Olaf Cardell; Jean-Christoph Caubet; Sevcan Celenk; Ewa Cichocka-Jarosz; Cemal Cingi; Mariana Couto; Nicolette Dejong; Stefano Del Giacco; Nikolaos Douladiris; Filippo Fassio; Jean-Luc Fauquert; Javier Fernandez; Montserrat Fernandez Rivas; Marta Ferrer; Carsten Flohr; James Gardner; Jon Genuneit; Philippe Gevaert; Anna Groblewska; Eckard Hamelmann; Hans Jürgen Hoffmann; Karin Hoffmann-Sommergruber; Lilit Hovhannisyan; Valérie Hox; Frode L Jahnsen; Omer Kalayci; Ayse Füsun Kalpaklioglu; Jörg Kleine-Tebbe; George Konstantinou; Marcin Kurowski; Susanne Lau; Roger Lauener; Antti Lauerma; Kirsty Logan; Antoine Magnan; Joanna Makowska; Heidi Makrinioti; Paraskevi Mangina; Felicia Manole; Adriano Mari; Angel Mazon; Clare Mills; Ervinç Mingomataj; Bodo Niggemann; Gunnar Nilsson; Markus Ollert; Liam O'Mahony; Serena O'Neil; Gianni Pala; Alberto Papi; Gianni Passalacqua; Michael Perkin; Oliver Pfaar; Constantinos Pitsios; Santiago Quirce; Ulrike Raap; Monika Raulf-Heimsoth; Claudio Rhyner; Paula Robson-Ansley; Rodrigo Rodrigues Alves; Zeljka Roje; Carmen Rondon; Odilija Rudzeviciene; Franziska Ruëff; Maia Rukhadze; Gabriele Rumi; Cansin Sackesen; Alexandra F Santos; Annalisa Santucci; Christian Scharf; Carsten Schmidt-Weber; Benno Schnyder; Jürgen Schwarze; Gianenrico Senna; Svetlana Sergejeva; Sven Seys; Andrea Siracusa; Isabel Skypala; Milena Sokolowska; Francois Spertini; Radoslaw Spiewak; Aline Sprikkelman; Gunter Sturm; Ines Swoboda; Ingrid Terreehorst; Elina Toskala; Claudia Traidl-Hoffmann; Carina Venter; Berber Vlieg-Boerstra; Paul Whitacker; Margitta Worm; Paraskevi Xepapadaki; Cezmi A Akdis
Journal:  Clin Transl Allergy       Date:  2012-11-02       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.